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Background: Primary melanoma of the CNS in children is extremely rare, and usually linked to congenital melanocytic naevus
syndrome, caused by mosaicism for oncogenic NRAS mutations. Outcome is fatal in all cases. Data from murine and in vitro
studies suggest that MEK inhibition is a possible therapeutic option.
Methods: Four children with NRAS-mutated CNS melanoma were treated with Trametinib on a compassionate basis.
Results: All four had an improvement in symptoms and objectively in signs. These varied from mild improvement for 1 month, to a
sustained symptom-free period of 9 months in one case. In all cases there was eventual disease progression through treatment,
followed by rapid death after discontinuation. There were no clinically-significant side effects.
Conclusions: Trametinib is the first therapy to show any objective or measurable effect in NRAS-mutated primary CNS melanoma,
with few side effects in this small series. The role of this therapy should be explored further in this rare paediatric tumour.
Primary CNS melanoma in childhood is extremely rare (CRUK,
2016), usually but not exclusively arising in the context of
congenital melanocytic naevus (CMN) syndrome (unpublished
data from our tertiary referral paediatric oncology department).
CMN syndrome is the association of congenital moles with extra-
cutaneous features such as congenital neurological malformations
(Kadonaga et al, 1992; Barkovich et al, 1994; Acosta et al, 2005;
Kinsler et al, 2008) and characteristic facies (Kinsler et al, 2012)
(Figure 1). The term CMN syndrome therefore incorporates the
term Neurocutaneous Melanosis, which is one particular pheno-
typic subset of the extra-cutaneous associations of CMN. In post-
natal life affected individuals are at increased risk of cutaneous and
CNS melanoma, with the peak incidence in childhood (Krengel
et al, 2006; Kinsler et al, 2017a). However, the majority of
congenital cutaneous and neurological abnormalities do not lead to
melanoma, even when neurological disease is symptomatic, and a
new classification of congenital neurological findings has been able
to identify high risk groups for all clinical outcomes including
all-site melanoma (Waelchli et al, 2015; Kinsler et al, 2017a).
This syndrome is caused in 80% of cases by post-zygotic
mosaicism for oncogenic mutations in codon 61 of NRAS (Kinsler
et al, 2013), or in other words that a single mutated cell in the
embryo leads to all the cutaneous and other congenital malforma-
tions, and predisposes to malignancy by acting as a first hit in a
multi-step process. Evidence for further mutation at the NRAS
locus leading from the congenital to the malignant state has been
demonstrated in a small number of cases, with loss of
heterozygosity of the normal allele (Kinsler et al, 2013) or
amplification of the mutant allele both described (Salgado et al,
2015). Copy-number abnormalities are also a very consistent
finding in melanoma in this condition, and the specific number/
pattern of multiple large gains and losses helps distinguish
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malignant from benign proliferations within the skin (Bastian et al,
2003), and also the CNS (Kinsler et al, 2017b).
Currently, the outlook for primary CNS melanoma in children
is extremely bleak, with a recent review of our prospective in-house
cohort (including these 4 cases) demonstrating 100% mortality
within 9 months of diagnosis (Kinsler et al, 2017a), comparable to
the data from a retrospective literature review (Neuhold et al,
2015). Our experience of systemic therapies for this disease include
Dacarbazine and Temozolomide, a single experience with anti-
CTLA-4 antibody therapy (Ipilimumab), and use of the mTOR
inhibitor Sirolimus in three patients, none of which have had any
measurable effect on symptoms or disease progression (unpub-
lished data and Kinsler et al, 2017a). Due to driver NRAS
mutations the use of selective BRAF inhibitors is contraindicated,
whereas targeting the more distal MAPK pathway is a possible
option. Data from a mouse model of NRAS codon 61 mosaicism
have demonstrated inhibition of leptomeningeal disease with
administration of a MEK inhibitor (Pawlikowski et al, 2015), with
supporting evidence of the critical role of NRAS from a further
murine model (Pedersen et al, 2013). One previous report of use in
a single paediatric case was of limited use as the drug was started
only days before death, although functional work in vitro was again
supportive (Kusters-Vandevelde et al, 2014). These data encour-
aged us to test Trametinib in a small series of patients with this rare
malignancy.
MATERIALS AND METHODS
We therefore obtained access to the MEK inhibitor Trametinib
for four children on a compassionate basis from Glaxo
SmithKline (Middlesex, UK) (patient phenotypic details in Table 1).
Trametinib was used initially at a dose of 0.0125mg kg 1 per day
in two patients (patients 1 and 2, Table 1); however, although both
had symptomatic benefit (reversal of neurological signs) this was of
short duration prior to rapid disease progression. When a higher
dose of 0.025mg kg 1 per day was established to be safe in on-
going phase I paediatric studies (GlaxoSmithKline, 2016) we
increased the dose to this level in two further patients (patients 3
and 4, Table 1). Prior to starting Trametinib all patients had
echocardiogram, ECG, ophthalmological exam and blood tests for
full blood count, urea and electrolytes, liver function tests, gamma
GT and creatinine kinase.
RESULTS
In all four patients we saw an objective improvement in symptoms
and signs. In patient 1 this was limited to recovery of a small
amount of movement in both upper limbs, from day 21 after
starting treatment, and after these had been paralysed for
approximately 2 months prior. This limited improvement was
sustained for 4 weeks, before rapid worsening in neurological
status related to intracerebral haemorrhage into the intraparench-
ymal tumour mass. Trametinib was stopped after 49 days of
therapy and she died 10 days later.
In patient 2, his parents reported a very rapid improvement in
the child’s mood, seeming much happier and less irritable within a
few days of starting treatment. His seizures stopped, having been
an ongoing problem for 3 months, and he was slowly weaned off
his anti-seizure medication and oral steroids. In addition, he
objectively regained power in his upper and lower limbs, as
assessed by neurological examination. This improvement was
sustained for 7 weeks before he suddenly decompensated,
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Figure 1. Examples of phenotype in congenital melanocytic naevus syndrome. Written consent was obtained for clinical photo publication.
(A) Example of severe cutaneous phenotype. (B) Diffuse melanotic leptomeningeal disease—this requires biopsy and both histological and genetic
testing before malignancy can be established, and should be viewed in the context of the baseline screening MRI of the CNS under 1 year. This
case was leptomeningeal melanoma.
BRITISH JOURNAL OF CANCER MEK inhibition in CNS melanoma in children
2 www.bjcancer.com |DOI:10.1038/bjc.2017.49
presenting with status epilepticus, and evidence of disease
progression on MRI. Trametinib was stopped on day 54 of therapy
and he died 3 weeks later from cord compression.
In patient 3, the drug was started much earlier in the disease,
when symptoms were intermittent acutely raised intracranial
pressure without other focal neurological signs. After 56 days of
therapy he had not had any further episodes of raised intracranial
pressure, and a reassessment MRI of the brain and spine with
contrast reported stable leptomeningeal disease with improvement
in the drainage of the lateral ventricles, and a further MRI at 139
days still showed stable disease. Based on previous patient disease
course these findings are very encouraging. This patient then
proceeded to have an entirely symptom-free period for a total of 9
months on Trametinib during which he continued to have normal
neurodevelopment. This was once again, however, followed by
sudden clinical and radiological disease progression, and death
from spinal cord compression three weeks after stopping
Trametinib.
In patient 4, there was no skin involvement, but the
leptomeningeal melanoma was indistinguishable from the other
cases. This has rarely been reported in the literature, and could
correspond to the same post-zygotic mutation affecting only the
neurological system (Dechaphunkul et al, 2011; Sutton et al, 2011;
Marana Perez et al, 2016; Szathmari et al, 2016). In this patient
there was marked reversal of pre-terminal cord compression one
week after the increase in dose of Trametinib, and a day after
starting Dexamethasone; however, the latter has not previously had
a sustained effect in our patients. The patient had been admitted to
a hospice in a moribund state but became suddenly asymptomatic
and was discharged home, and was then symptom-free for two
months before rapid disease progression, and death within a week
of stopping Trametinib.
Importantly, thus far, side effects have been very few and not
clinically relevant (Table 1) in any patient.
DISCUSSION
Trametinib (MEK inhibition) is the first medical therapy to have
had any observable effect in primary NRAS-driven CNS melanoma
in children in our cohort. Furthermore, it appears to have
markedly improved disease symptoms in some cases compared
to the usual course we have seen in our cohort, allowing improved
quality of life for affected children in their own homes, with no
clinically-significant side effects in these first four cases. The failure
to stop disease progression altogether is likely to be due to the
additional mutations seen in the melanoma over and above the
NRAS driver mutation. Although the disease has eventually
progressed through treatment this is an important new first step
in finding therapy for this condition.
Table 1. Phenotype, genotype, response and outcome of patients with primary CNS melanoma treated with Trametinib, in order
of commencing treatment
Patient
number Sex
Age at
diagnosis
of
melanoma Outcome
Skin disease
classification
(Krengel
et al, 2013)
Screening
MRI CNS
under 1 year
Primary
melanoma
site
Leptomeningeal
tissue NRAS
genotype
Initial and
final
Trametinib
doses
Temporary
response
Side
effects
requiring
treatment
1 Female 1.8y Death age
2.2y
Multiple CMN,
no clearly larger
naevus, total
4400 naevi all
over body and
head, no nodules
Concensus
classification: S3,
C1, R0, N0, H1
Complex
congenital
neurological
disease
CNS, diffuse
leptomeningeal
melanoma,
infiltration of the
underlying
parenchyma, VP
shunt required
c.181C4A; p.Q61K 0.0125mgkg 1
per day
Limited
improvement
in upper limb
movement
None.
Temporary
grade 1 rise
in creatine
kinase
2 Male 4.0y Death, age
4.6y
Multiple CMN,
largest in cape
distribution, non-
circumferential,
projected adult
size 20–40 cm,
total 100–200
naevi,
Concensus
classification
L1, S3, Trunk,
C0, R0, N0, H1
Complex
congenital
neurological
disease
CNS, diffuse
leptomeningeal
melanoma, VP
shunt required
c.181C4A; p.Q61K 0.0125mgkg 1
per day
Decreased
irritability,
cessation of
seizures,
improvement
in limb function
None
3 Male 1.5y Death age
2.3y
Multiple CMN,
largest
circumferential
bathing trunk
distribution,
projected adult
size 460 cm,
total 50–100
naevi, Concensus
classification: G2,
S3, Trunk, C0, R1,
N0, H2
Complex
congenital
neurological
disease
CNS, diffuse
leptomeningeal
melanoma, VP
required.
c.181C4A; p.Q61K 0.0125–
0.025mgkg 1
per day
Cessation of
symptoms of
raised
intracranial
pressure,
stabilisation of
MRI findings
None.
Temporary
grade 1
increase in
creatine
kinase
4 Female 0.9y Death age
1.5y
No skin lesions Not done CNS, diffuse
leptomeningeal
melanoma,
infiltration of
underlying
parenchyma, VP
shunt required
c.181C4A; p.Q61K 0.0125–
0.025mgkg 1
per day
Cessation of
symptoms of
spinal cord
compression
and raised
intracranial
pressure
None
Abbreviations: CMN¼ congenital melanocytic naevus; CNS¼ central nervous system; y¼ years.
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